CELL INTELLIGENCE · 肿瘤细胞治疗研究

DLBCL 免疫治疗中的巨噬细胞吞噬检查点：从 CD47 到 CD200 的证据成熟度框架

Macrophage phagocytosis checkpoints in DLBCL immunotherapy: an evidence-maturity framework from CD47 to CD200.

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

难治性特发性炎性肌病相关间质性肺疾病的新型治疗策略

Novel therapies for refractory idiopathic inflammatory myopathy-associated interstitial lung disease.

CAR-T 细胞对比双特异性抗体治疗复发/难治性套细胞淋巴瘤：系统综述与荟萃分析

CAR T-cell vs bispecific antibodies in relapsed/refractory mantle cell lymphoma: a systematic review and meta-analysis.

CAR-T 细胞疗法相比双特异性抗体显示出更高的 CR 率，支持其作为 R/R MCL 有效三线治疗的作用。需要随机试验来证实这些发现。

Mosunetuzumab 联合 polatuzumab vedotin 治疗 BTK 抑制剂治疗后的复发/难治性 MCL：一项 2 期研究

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

大辩论：CAR-T 细胞疗法对比双特异性抗体治疗 B 细胞淋巴瘤

The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma.

老年套细胞淋巴瘤：生物学风险分层、体能适应性策略与未满足需求

Mantle Cell Lymphoma in Geriatric Patients: Biologic Risk Stratification, Fitness-Adapted Strategies, and Unmet Needs.

CD19 CAR-T 细胞治疗 Hematologic Diseases：I 期临床试验（Roswell Park Cancer）

Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Rela

这是一项 I 期注册临床试验，评估 CAR-T 细胞治疗相关疾病的安全性、可行性及初步疗效。当前状态：尚未开始招募。计划入组 21 例。试验地点：美国 · 布法罗（共 1 个中心）。登记号：NCT07701889。

疗效-安全性权衡与患者选择：一项为 R/R B-NHL 中 CAR-T 与双特异性抗体临床选择提供依据的 meta 分析

Efficacy-safety trade-off and patient selection: a meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL.

基于重复时间-事件模型的 Epcoritamab 剂量递增方案选择与优化以降低细胞因子释放综合征风险

Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.